Statistics from Altmetric.com
A 70-year-old woman with metastatic squamous cell carcinoma of the lung was admitted to hospital in September 2020 with a 3-week history of generalised abdominal pain and postprandial vomiting. She had been diagnosed with squamous cell carcinoma of the lung with a programmed death ligand-1 expression of 90% and only small-volume lung metastases in February 2019. She was soon after commenced on first-line pembrolizumab, a monoclonal antibody targeting programmed cell death protein 1 (PD- 1), which led to a reduction in the size of both primary tumour and metastatic lung nodules. Medical history was significant for dyspepsia diagnosed several years prior and treated with long-term omeprazole 40 mg once a day, chronic obstructive pulmonary disease, ischaemic heart disease and type 2 diabetes. She had no history of non-steroidal …
Contributors SG wrote and submitted the manuscript. MAS wrote and edited the script. DHJ provided information to write the report and edited the manuscript. RPL provided the endoscopy images and wrote/edited the manuscript. UM provided the annotated histology and edited the manuscript. All authors have read and approved this submission.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests RPL has received educational grants from Ferring, Pfizer and Vifor Pharma. MAS served as a speaker, a consultant and/or an advisory board member for Sandoz, Janssen, Takeda, MSD, Falk, Samsung Bioepis, Galapagos and Bristol-Myers Squibb. DHJ has received educational grants from Janssen, Bayer, BMS and EUSA Pharma and has served as a speaker/an advisory board member for Janssen, AstraZeneca, MSD and Pfizer.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.